ATYR
What one share of aTYR PHARMA holds
Biological Products, (No Diagnostic Substances)
We are a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans.
aTYR PHARMA’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.62 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.56 |
| Cash and investments | $0.16 |
| Book value | $0.50 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$2.44 | $0.03 | −$2.26 | — | $2.64 |
| 2017 | — | −$26.13 | $0.71 | −$23.67 | — | — |
| 2018 | — | −$16.11 | $0.28 | −$14.78 | — | $15.39 |
| 2020 | $1.14 | −$1.77 | $0.02 | −$1.69 | — | $2.87 |
| 2021 | $0.00 | −$1.77 | $0.01 | −$1.74 | — | $3.93 |
| 2022 | $0.37 | −$1.60 | $0.06 | −$1.53 | — | $2.42 |
| 2023 | $0.01 | −$0.94 | $0.08 | −$0.70 | — | $1.43 |
| 2024 | $0.00 | −$0.86 | $0.00 | −$0.93 | — | $0.83 |
| 2025 | $0.00 | −$0.80 | $0.00 | −$0.67 | — | $0.69 |